Propranolol-induced increases in target-biting attack.

J Matray-Devoti; G C Wagner

doi:10.1016/0091-3057(93)90223-g

Home/Archive/PubMed

PubMed · 8309973

Propranolol-induced increases in target-biting attack.

J Matray-Devoti·G C Wagner

View original source ↗Export metadata ↓

Abstract

The effect of a beta-adrenoreceptor blocking agent on defensive aggression in mice was evaluated. Acute doses of d,l-propranolol (0.2, 0.4, 0.8, 1.6, 3.2, 6.4, and 12.8 mg/kg) were administered to male Rockland-Swiss mice prior to testing in a target-biting paradigm. Baseline conditions established a high target-biting rate low biting rate during a 15-s tone stimulus preceding the next shock. Every dose of propranolol increased target-biting rates above baseline during each interval with one exception: 0.4 mg/kg decreased the biting rate immediately after delivery of the tail shock. The overall increase in aggression observed following dosing with propranolol was not expected from a review of the clinical literature. These results are discussed in reference to propranolol's known effects on the brain serotoninergic systems and the use of an animal model of defensive aggression.

Explore related subjects

Aggression Animals Dose-Response Relationship, Drug Male Mice Propranolol Serotonin Stimulation, Chemical Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

J Matray-Devoti, G C Wagner. 1993. Propranolol-induced increases in target-biting attack.. https://doi.org/10.1016/0091-3057(93)90223-g

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1999

[Male depression--stress reaction combined with serotonin deficiency?].

An educational programme on depressive disorders, given to general practitioners on the Swedish island of Gotland, resulted in a statistically significant reduction of the suicide rate among women, though that among men was virtually unaffected. Further analysis showed the profile of depression among men to differ from that among women, the male pattern typically being more characterised by irritability, aggressiveness, acting out, antisocial behaviour and alcohol abuse, and reduced impulse control and stress tolerance. Predisposition to affective disorders, suicide and alcoholism seems to be genetically determined. The syndrome, which is not easily recognised and is seldom properly treated or prevented, seems to be related to central serotonin deficiency and hypercortisolaemia.

Aggression↗

PubMed1999

Aggression and anger-related traits associated with a polymorphism of the tryptophan hydroxylase gene.

BACKGROUND: Central nervous system (CNS) serotonergic activity correlates inversely with human aggressive behavior, and individual differences in aggressive disposition are at least partially heritable. This study was conducted to evaluate the possible association between measures of antagonistic behavior and an intronic polymorphism of the gene coding for tryptophan hydroxylase (TPH), the rate-limiting enzyme in serotonin biosynthesis. METHODS: Locally recruited men and women (n = 251) were genotyped for the A218C polymorphism located in intron 7 of the TPH gene. All subjects were administered standard interview and questionnaire indices of aggression and anger-related traits of personality; in a portion of subjects, CNS serotonergic activity was assessed by neuropsychopharmacologic challenge (prolactin response to fenfluramine hydrochloride). RESULTS: Persons having any TPH U allele scored significantly higher on measures of aggression and tendency to experience unprovoked anger and were more likely to report expressing their anger outwardly than individuals homozygous for the alternate L allele. In men, but not women, peak prolactin response to fenfluramine was also attenuated among subjects having any U allele, relative to LL homozygotes. CONCLUSIONS: Individual differences in aggressive disposition are associated with an intronic polymorphism of the TPH gene in a nonpatient sample of community-derived volunteers.

Aggression↗

PubMed1999

Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.

Aggressive behavior of psychotic patients impacts all aspects of their clinical care. Better treatments to address this problem are needed, and atypical antipsychotics, such as clozapine, risperidone, and perhaps quetiapine, have shown promise. However, studying the psychopharmacology of aggression is difficult because of the many methodological problems that arise in the design of appropriate clinical trials. These include imprecise definitions of aggression, the difficulty of measuring outcome because of the relative rarity of aggressive events, bias in the selection of patients for study, inadequate and inappropriate control groups, and inattention to comorbidities and concomitant medications in analyzing results. Since the usual outcome measure is the aggressive event rate, a large sample size and lengthy baseline and trial periods are required when this rate is low. Furthermore, formidable practical and ethical obstacles interfere with the many sound techniques (e.g. randomization) used in typical designs of psychopharmacological clinical trials. Current research methods should be modified and new ones developed in order to progress in assessing the antiaggressive effects of treatments.

Aggression↗